SCHEMBL7202567

SCHEMBL7202567

NC(=O)N1CCC(S(=O)(=O)c2ccc(-c3cccc(F)c3)cc2)C(O)(C(=O)O)C1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP13 P45452 2/20 0.40
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP3 P08254 1/20 0.38
MMP7 P09237 1/20 0.38
MMP9 P14780 1/20 0.38
USP2 O75604 7/20 0.38
CYP3A4 P08684 6/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
ALDH1A1 P00352 4/20 0.38
HPGD P15428 2/20 0.38
MAPK1 P28482 2/20 0.38
HIF1A Q16665 2/20 0.38
HSD17B10 Q99714 2/20 0.38
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7201540 0.90 ADAMTS4 (0.39) MMP13MMP1MMP3CA12CA1
SCHEMBL7201014 0.90 SMN1; SMN2 (0.41) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7205956 0.88 MMP13 (0.53) MMP13MMP1F10ICMTKDM2B
SCHEMBL7290273 0.88 MGLL (0.41) MMP13MMP1CA12CA1CA2
SCHEMBL7207978 0.86 PARP10 (0.45) MMP13MMP1MMP2MMP3MMP9
SCHEMBL7201767 0.86 NAAA (0.44) MMP13ALDH1A1CA12CA1CA2
SCHEMBL7204066 0.83 ALDH1A1 (0.38) MMP13MMP1MMP3ALDH1A1CA12
SCHEMBL7300738 0.83 MMP13 (0.48) MMP13MMP1ALDH1A1HPGDMEN1
SCHEMBL7205673 0.83 MMP1 (0.39) MMP13MMP1ALDH1A1F10TMPRSS6
SCHEMBL7201593 0.83 MAOB (0.49) MMP13MMP1MMP2MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6608104-B2 Antiarthritic agents; anticancer agents PFIZER INC 2003-08-19 US disclosed
US-20020019534-A1 Gem substituted hydroxamic acids PFIZER INC. 2002-02-14 US disclosed
EP-1138680-A1 Gem substituted sulfonyl hydroxamic acids as MMP inhibitors Pfizer Products Inc. (US) 2001-10-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019534-A1 Gem substituted hydroxamic acids MMP14, TOP2A, ADAMTS1 MMP13 4/4885MMP1 8/4885MMP2 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.